HHS Backs NIH Rejection Of Xtandi Petition Despite March-In Framework

By Gabrielle Wanneh / February 6, 2024 at 5:10 PM
HHS Secretary Xavier Becerra is standing behind the National Institutes of Health’s (NIH) decision to reject a petition for the government to invoke its right to march-in on the patents of the prostate cancer drug Xtandi and have qualified generic drug makers make lower-cost alternatives of the drug, even though the Biden administration is on the cusp of considering costs as a credible factor for deciding when march-in rights should be used. In a letter sent to the petitioners Monday...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.